Earnings Releases, Technical Updates, FDA Acceptances, and New Products - Research Reports on Newfield Exploration, YPF, HCA, Actavis and 3M

NEW YORK, August 4, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Newfield Exploration Company (NYSE: NFX), YPF SA (NYSE: YPF), HCA Holdings Inc (NYSE: HCA), Actavis plc (NYSE: ACT) and 3M Company (NYSE: MMM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5394-100free.

--
Newfield Exploration Company Research Reports
On July 29, 2014, Newfield Exploration Company (Newfield Exploration) reported its unaudited financial results for Q2 2014. During the quarter, the Company's revenues grew considerably by 39.8% YoY to $608 million, with around 55% of the increase attributable to increases in oil production in its onshore Gulf Coast, Rocky Mountains and Mid-Continent regions and around 17% on account of the higher oil prices. Total production in the quarter increased 21.0% YoY to 11,639 MBOE, with natural gas liquids witnessing the highest jump in production at 59.5%, crude oil and condensate production increasing 33.4%, and natural gas liquid production improving slightly by 2.7%. The Company reported a loss per share of $0.16 for the quarter as compared to a profit of $0.82 per share in Q2 2013. According to Newfield Exploration, net income would have been $59 million, or $0.43 per share, excluding an unrealized loss on commodity derivatives. The full research reports on Newfield Exploration are available to download free of charge at:

http://www.analystsreview.com/Aug-04-2014/NFX/report.pdf

--
YPF SA Research Reports
On July 30, 2014, the stock of YPF SA (YPF) continued its upward journey for the second consecutive session, closing at $38.91, up 9.33% from its previous day's close. Markets Emerging reported that stocks of Argentine companies climbed higher during the day as members of Adeba - Argentina's banking association worked towards a deal to avert a second default by Argentina in 13 years. The Company's stock opened at $38.91, and fluctuated within the range of $38.12 - $41.74 during the trading session. The Company's stock price gained 19.06% over the past one month of trading while the NYSE Composite marginally declined by 0.45% during the same time period. The full research reports on YPF are available to download free of charge at:

http://www.analystsreview.com/Aug-04-2014/YPF/report.pdf

--
HCA Holdings Inc Research Reports
On July 29, 2014, HCA Holdings Inc (HCA) reported its financial results for Q2 2014. During the quarter, the Company's revenues grew by 9.2% YoY to $9.2 billion. The number of hospitals in operation increased to 165 as compared to 161 at the end of Q2 2013. As compared to the second quarter of 2013, there was a modest growth of 2.3% in the number of admissions, revenue per equivalent admission increased by 5.4%, patient days grew by 4.2%, and occupancy increased to 54.6% as against 53.8% in Q2 2013. The Company's diluted earnings per share came in at $1.07, up by 17.6% as compared to $0.91 in the comparable quarter in 2013. The full research reports on HCA are available to download free of charge at:

http://www.analystsreview.com/Aug-04-2014/HCA/report.pdf

--
Actavis plc Research Reports
On July 21, 2014, Actavis plc (Actavis), together with Medicines360, a non-profit women's health pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360's New Drug Application (NDA) for Levosert™, a hormonal intrauterine contraceptive (IUC) for use by women to prevent pregnancy. Acceptance for filing means that according to FDA, the application is sufficiently complete to allow a substantive review. Actavis stated that under the Prescription Drug User Fee Act, the FDA's goal under standard review is to review and act on the NDA by February 28, 2015. Medicines360 and Actavis entered into a partnership in June 2013 to make Levosert™ available in the U.S. commercially and at an affordable price in U.S. public sector clinics. The full research reports on Actavis are available to download free of charge at:

http://www.analystsreview.com/Aug-04-2014/ACT/report.pdf

--
3M Company Research Reports
On July 30, 2014, 3M Company (3M) reported that its Scotch Brand is introducing new products for the new school season to help add personality and creativity to schoolwork, home organization and classroom décor. Some of the products offered by the Company for students include Scotch Expressions Tapes and Decals, Scotch Magic Tape Dispensers, and Scotch Designer Student Scissors. Product offerings for parents include Scotch Thermal Laminators, Scotch Repositionable Magnetic Tape, Scotch No Run Multi-Purpose Glue, and Scotch Expressions Multi-Roll Tape Dispenser. The Company also offers products for teachers, which include Scotch Titanium Utility Knives, Scotch Double-Sided Tape Applicator, amongst others. The Company stated that Scotch Brand products are available online and at select office superstores and mass retailers nationwide. The full research reports on 3M are available to download free of charge at:

http://www.analystsreview.com/Aug-04-2014/MMM/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review